What is MitrAssist?
MitrAssist operates at the intersection of interventional cardiology and medical engineering, specializing in minimally invasive solutions for patients suffering from life-threatening Mitral Regurgitation (MR). The company's core innovation is a sophisticated valve-in-valve implant designed to integrate seamlessly with existing anatomical structures, offering a viable alternative to traditional open-heart surgery. By focusing on shorter procedure times and expedited patient recovery, MitrAssist is effectively disrupting the standard of care for patients who were previously considered inoperable or high-risk. Their technology is engineered to accommodate diverse anatomical variations, ensuring broad applicability across various age demographics and clinical profiles.
How much funding has MitrAssist raised?
MitrAssist has raised a total of $31M across 2 funding rounds:
Unspecified
$1M
Private Equity
$30M
Unspecified (2013): $1M, investors not publicly disclosed
Private Equity (2017): $30M led by Shanghai Fosun Pharmaceutical Co. Ltd. and Ping Ang Insurance Company
Key Investors in MitrAssist
Shanghai Fosun Pharmaceutical Co. Ltd.
A leading healthcare conglomerate based in Shanghai, focusing on the research, development, and manufacturing of innovative pharmaceutical and medical device solutions.
Ping An Insurance Company
A diversified financial services group headquartered in Shenzhen, specializing in insurance, banking, and strategic investments within the healthcare and technology sectors.
Undisclosed Investor
An undisclosed investor participating in the early-stage financing round to support initial product development and clinical feasibility.
What's next for MitrAssist?
With this major enterprise-level funding, MitrAssist is poised to transition into a phase of aggressive clinical validation and market penetration. The strategic allocation of capital will likely prioritize the scaling of manufacturing capabilities and the expansion of multi-center clinical trials to support regulatory submissions in key global markets. As the company moves forward, the focus will remain on refining its valve-in-valve delivery systems and establishing long-term partnerships with leading cardiovascular centers. This growth trajectory suggests a clear path toward becoming a dominant player in the structural heart disease market, ultimately aiming to improve health outcomes for a global patient base.
See full MitrAssist company page
